Compare · LGND vs NVO
LGND vs NVO
Side-by-side comparison of Ligand Pharmaceuticals Incorporated (LGND) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LGND and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $169.01B, about 28.4x LGND ($5.95B).
- Over the past year, LGND is up 77.4% and NVO is down 35.0% - LGND leads by 112.4 points.
- LGND has been more active in the news (7 items in the past 4 weeks vs 6 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 11 for LGND).
- Company
- Ligand Pharmaceuticals Incorporated
- Novo Nordisk A/S
- Price
- $299.53+0.30%
- $38.17-3.12%
- Market cap
- $5.95B
- $169.01B
- 1M return
- +6.76%
- -18.67%
- 1Y return
- +77.39%
- -35.01%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 6
- Recent ratings
- 11
- 25
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LGND
- Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
- Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
- Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
- Director Zimmermann Martine sold $342,000 worth of shares (1,200 units at $285.00), decreasing direct ownership by 24% to 3,897 units (SEC Form 4)
- CLO & Secretary Reardon Andrew sold $1,430,434 worth of shares (5,000 units at $286.09) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 36,514 units (SEC Form 4)
- Amendment: Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Financial Statements and Exhibits
- Ligand to Participate in September Investor Conferences
- Chief Financial Officer Espinoza Octavio exercised 31,641 shares at a strike of $56.91 and sold $9,241,229 worth of shares (31,641 units at $292.06) as part of a pre-agreed trading plan (SEC Form 4)
- Director Haas Jason exercised 6,138 shares at a strike of $51.56 and sold $2,090,062 worth of shares (7,138 units at $292.81), decreasing direct ownership by 20% to 3,981 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S